Feature Updates

2024 ASCO Reveals These Pharmaceutical Research and Development Trends

28 May 2024
3 min read

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be grandly held in Chicago from May 31 to June 4, Eastern Time, USA. As one of the largest, most academically prestigious, and authoritative clinical oncology conferences in the world, ASCO gathers numerous world-class oncology experts to share and discuss the most cutting-edge international clinical oncology research findings and cancer treatment technologies. Many significant research discoveries and clinical trial results also choose the ASCO Annual Meeting for their initial release.

To facilitate systematic and intuitive searching and research of ASCO conference clinical results, the synapse database has launched a new dedicated section for the 2024 ASCO conference clinical results. It has standardized and visually displayed over 1,500 ASCO conference data entries that have been disclosed so far. From this vast amount of data, we have also derived some analysis and insights into pharmaceutical research and development trends. Let's take a closer look!

According to the synapse database analysis, in this ASCO conference, the indication with the most disclosed data is advanced malignant solid tumors, followed by non-small cell lung cancer, solid tumors, metastatic colorectal cancer, multiple myeloma, and others.

表格

中度可信度描述已自动生成

The disclosed meeting data indicates that the majority, 27%, of the projects are in Phase IV of clinical development.

图表, 旭日形

描述已自动生成

The conference information involves a significant number of targets, including PD-1, Tubulin, PDL1, VEGFR2, VEGFR1, c-Kit, etc.

图表, 条形图

描述已自动生成

The majority of clinical results continue to be dominated by multinational pharmaceutical companies.

图表

中度可信度描述已自动生成

In this conference, the most disclosed drug was Pembrolizumab. Pembrolizumab is a monoclonal antibody that can bind to the PD-1 receptor, thereby blocking the interaction between PD-1 and PD-L1/PD-L2. This mechanism lifts the PD-1 pathway-mediated immunosuppression and restores tumor-specific T cell immunity. Nivolumab followed closely with 31 disclosed information items.

图表, 瀑布图

描述已自动生成

How can you search for and view the clinical results data of conferences you are interested in through the Synapse database? (Click here to directly access the search interface for querying clinical results data.)

Under the "Clinical Results" option, select ASCO 2024 and click search. You will obtain comprehensive information on ASCO 2024. Additionally, the Clinical Results Database offers multi-dimensional filtering and screening options based on drug, indication, target, company, etc., helping you quickly locate the data you need.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

On the retrieval page, a card-based list view is provided, allowing you to intuitively grasp the core information of individual results.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Clicking the title allows you to navigate to the details page to view all data of this result.

图形用户界面, 文本, 应用程序, Teams

描述已自动生成

In the Key Indicators section, both list and flowchart formats are provided, making core indicator data information clear and easy to understand. Additionally, an image download and save feature is available, making it convenient for you to create reports or share with colleagues.

图形用户界面, 应用程序, Teams

描述已自动生成

图示

中度可信度描述已自动生成

Finally, if you need to download these results, you can easily select the checkboxes on the left side of the list or directly click the "Export" button to download the data for personalized analysis and file sharing.

图形用户界面, 文本, 应用程序

描述已自动生成

Currently, the Clinical Results Database has already covered data sources such as conferences, ClinicalTrials.gov, PubMed, news articles, and package inserts. We will continue to expand new data sources and continuously improve the functionalities and data within the results database. Come and experience it now!

Dyne Therapeutics Unveils Positive ACHIEVE and DELIVER Study Results for DYNE-101 in DM1 and DYNE-251 in DMD
Latest Hotspot
3 min read
Dyne Therapeutics Unveils Positive ACHIEVE and DELIVER Study Results for DYNE-101 in DM1 and DYNE-251 in DMD
28 May 2024
Dyne Therapeutics Reveals Latest Clinical Results from ACHIEVE Study of DYNE-101 in DM1 and DELIVER Study of DYNE-251 in DMD Highlighting Significant Effects on Key Disease Indicators and Improvements in Several Functional Outcomes.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 28
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 28
28 May 2024
May 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Rapid-Acting Insulin AT278 Proves Superior in Phase I Trial for Overweight Type 2 Diabetics
Latest Hotspot
3 min read
Rapid-Acting Insulin AT278 Proves Superior in Phase I Trial for Overweight Type 2 Diabetics
28 May 2024
AT278 Ultra-Concentrated Rapid-Acting Insulin Shows Superiority in Phase I Trial for Overweight and Obese Type 2 Diabetics.
Read →
GigaGen Begins Phase 1 Trial, Administers First Dose of GIGA-564 to Solid Tumor Patient
Latest Hotspot
3 min read
GigaGen Begins Phase 1 Trial, Administers First Dose of GIGA-564 to Solid Tumor Patient
28 May 2024
GigaGen Initiates Phase 1 Trial, Administers Initial Dose of GIGA-564 Anti-CTLA-4 Drug Candidate to Advanced Solid Tumor Patient.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.